nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—PTGS2—urinary bladder cancer	0.528	1	CbGaD
Drospirenone—BCHE—Cisplatin—urinary bladder cancer	0.0941	0.396	CbGbCtD
Drospirenone—PTGS2—Cisplatin—urinary bladder cancer	0.0724	0.305	CbGbCtD
Drospirenone—PTGS2—Etoposide—urinary bladder cancer	0.0712	0.299	CbGbCtD
Drospirenone—AR—scrotum—urinary bladder cancer	0.026	0.242	CbGeAlD
Drospirenone—AR—penis—urinary bladder cancer	0.0118	0.109	CbGeAlD
Drospirenone—NR3C2—prostate gland—urinary bladder cancer	0.00379	0.0353	CbGeAlD
Drospirenone—PGR—prostate gland—urinary bladder cancer	0.00352	0.0328	CbGeAlD
Drospirenone—NR3C2—seminal vesicle—urinary bladder cancer	0.00321	0.0298	CbGeAlD
Drospirenone—AR—prostate gland—urinary bladder cancer	0.00281	0.0261	CbGeAlD
Drospirenone—NR3C2—smooth muscle tissue—urinary bladder cancer	0.00268	0.025	CbGeAlD
Drospirenone—PGR—epithelium—urinary bladder cancer	0.00259	0.0241	CbGeAlD
Drospirenone—NR3C2—renal system—urinary bladder cancer	0.00258	0.024	CbGeAlD
Drospirenone—NR3C2—urethra—urinary bladder cancer	0.00254	0.0236	CbGeAlD
Drospirenone—PGR—smooth muscle tissue—urinary bladder cancer	0.00249	0.0232	CbGeAlD
Drospirenone—AR—seminal vesicle—urinary bladder cancer	0.00237	0.0221	CbGeAlD
Drospirenone—BCHE—prostate gland—urinary bladder cancer	0.00228	0.0213	CbGeAlD
Drospirenone—NR3C2—female reproductive system—urinary bladder cancer	0.00207	0.0193	CbGeAlD
Drospirenone—AR—epithelium—urinary bladder cancer	0.00206	0.0192	CbGeAlD
Drospirenone—AR—smooth muscle tissue—urinary bladder cancer	0.00199	0.0185	CbGeAlD
Drospirenone—BCHE—seminal vesicle—urinary bladder cancer	0.00193	0.018	CbGeAlD
Drospirenone—PGR—female reproductive system—urinary bladder cancer	0.00192	0.0179	CbGeAlD
Drospirenone—AR—renal system—urinary bladder cancer	0.00191	0.0178	CbGeAlD
Drospirenone—AR—urethra—urinary bladder cancer	0.00188	0.0175	CbGeAlD
Drospirenone—NR3C2—vagina—urinary bladder cancer	0.00187	0.0174	CbGeAlD
Drospirenone—PTGS2—prostate gland—urinary bladder cancer	0.00176	0.0164	CbGeAlD
Drospirenone—PGR—vagina—urinary bladder cancer	0.00174	0.0162	CbGeAlD
Drospirenone—Thromboembolic event—Methotrexate—urinary bladder cancer	0.00173	0.0423	CcSEcCtD
Drospirenone—Embolism—Thiotepa—urinary bladder cancer	0.00169	0.0412	CcSEcCtD
Drospirenone—BCHE—smooth muscle tissue—urinary bladder cancer	0.00162	0.015	CbGeAlD
Drospirenone—AR—female reproductive system—urinary bladder cancer	0.00153	0.0143	CbGeAlD
Drospirenone—PTGS2—seminal vesicle—urinary bladder cancer	0.00149	0.0138	CbGeAlD
Drospirenone—Venous thromboembolism—Epirubicin—urinary bladder cancer	0.00148	0.0362	CcSEcCtD
Drospirenone—AR—vagina—urinary bladder cancer	0.00139	0.0129	CbGeAlD
Drospirenone—Venous thromboembolism—Doxorubicin—urinary bladder cancer	0.00137	0.0335	CcSEcCtD
Drospirenone—PTGS2—epithelium—urinary bladder cancer	0.00129	0.012	CbGeAlD
Drospirenone—BCHE—female reproductive system—urinary bladder cancer	0.00125	0.0116	CbGeAlD
Drospirenone—PTGS2—smooth muscle tissue—urinary bladder cancer	0.00125	0.0116	CbGeAlD
Drospirenone—NR3C2—lymph node—urinary bladder cancer	0.00121	0.0113	CbGeAlD
Drospirenone—PTGS2—renal system—urinary bladder cancer	0.0012	0.0112	CbGeAlD
Drospirenone—PTGS2—urethra—urinary bladder cancer	0.00118	0.011	CbGeAlD
Drospirenone—BCHE—vagina—urinary bladder cancer	0.00113	0.0105	CbGeAlD
Drospirenone—PGR—lymph node—urinary bladder cancer	0.00112	0.0105	CbGeAlD
Drospirenone—Loss of libido—Methotrexate—urinary bladder cancer	0.00101	0.0247	CcSEcCtD
Drospirenone—PTGS2—female reproductive system—urinary bladder cancer	0.00096	0.00894	CbGeAlD
Drospirenone—AR—lymph node—urinary bladder cancer	0.000896	0.00834	CbGeAlD
Drospirenone—PTGS2—vagina—urinary bladder cancer	0.000869	0.00808	CbGeAlD
Drospirenone—Embolism venous—Epirubicin—urinary bladder cancer	0.000864	0.0211	CcSEcCtD
Drospirenone—Embolism venous—Doxorubicin—urinary bladder cancer	0.000799	0.0195	CcSEcCtD
Drospirenone—BCHE—lymph node—urinary bladder cancer	0.000729	0.00679	CbGeAlD
Drospirenone—Embolism—Methotrexate—urinary bladder cancer	0.000726	0.0177	CcSEcCtD
Drospirenone—Embolism—Epirubicin—urinary bladder cancer	0.000679	0.0166	CcSEcCtD
Drospirenone—Cerebrovascular accident—Gemcitabine—urinary bladder cancer	0.000674	0.0165	CcSEcCtD
Drospirenone—Nausea—Valrubicin—urinary bladder cancer	0.000662	0.0162	CcSEcCtD
Drospirenone—Cerebrovascular accident—Cisplatin—urinary bladder cancer	0.000629	0.0154	CcSEcCtD
Drospirenone—Embolism—Doxorubicin—urinary bladder cancer	0.000628	0.0154	CcSEcCtD
Drospirenone—Thrombosis—Epirubicin—urinary bladder cancer	0.000616	0.015	CcSEcCtD
Drospirenone—Thrombosis—Doxorubicin—urinary bladder cancer	0.00057	0.0139	CcSEcCtD
Drospirenone—PTGS2—lymph node—urinary bladder cancer	0.000562	0.00523	CbGeAlD
Drospirenone—Breast disorder—Cisplatin—urinary bladder cancer	0.000557	0.0136	CcSEcCtD
Drospirenone—Haemoglobin—Thiotepa—urinary bladder cancer	0.000546	0.0134	CcSEcCtD
Drospirenone—Haemorrhage—Thiotepa—urinary bladder cancer	0.000544	0.0133	CcSEcCtD
Drospirenone—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.000502	0.0123	CcSEcCtD
Drospirenone—Breast pain—Epirubicin—urinary bladder cancer	0.0005	0.0122	CcSEcCtD
Drospirenone—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.000499	0.0122	CcSEcCtD
Drospirenone—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.000494	0.0121	CcSEcCtD
Drospirenone—Angiopathy—Thiotepa—urinary bladder cancer	0.000493	0.0121	CcSEcCtD
Drospirenone—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.000491	0.012	CcSEcCtD
Drospirenone—Mental disorder—Thiotepa—urinary bladder cancer	0.000476	0.0116	CcSEcCtD
Drospirenone—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.000468	0.0114	CcSEcCtD
Drospirenone—Myocardial infarction—Cisplatin—urinary bladder cancer	0.000465	0.0114	CcSEcCtD
Drospirenone—Breast pain—Doxorubicin—urinary bladder cancer	0.000462	0.0113	CcSEcCtD
Drospirenone—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00046	0.0112	CcSEcCtD
Drospirenone—Haemorrhage—Gemcitabine—urinary bladder cancer	0.000457	0.0112	CcSEcCtD
Drospirenone—Nausea—Mitomycin—urinary bladder cancer	0.000456	0.0111	CcSEcCtD
Drospirenone—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000452	0.011	CcSEcCtD
Drospirenone—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00045	0.011	CcSEcCtD
Drospirenone—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000432	0.0106	CcSEcCtD
Drospirenone—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000429	0.0105	CcSEcCtD
Drospirenone—Myocardial infarction—Etoposide—urinary bladder cancer	0.000426	0.0104	CcSEcCtD
Drospirenone—Angiopathy—Gemcitabine—urinary bladder cancer	0.000415	0.0101	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.0004	0.00978	CcSEcCtD
Drospirenone—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000379	0.00926	CcSEcCtD
Drospirenone—Skin disorder—Thiotepa—urinary bladder cancer	0.000375	0.00917	CcSEcCtD
Drospirenone—Erythema multiforme—Etoposide—urinary bladder cancer	0.000369	0.00902	CcSEcCtD
Drospirenone—Angiopathy—Etoposide—urinary bladder cancer	0.000354	0.00866	CcSEcCtD
Drospirenone—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000345	0.00843	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000337	0.00823	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000333	0.00815	CcSEcCtD
Drospirenone—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000323	0.00789	CcSEcCtD
Drospirenone—Mood swings—Methotrexate—urinary bladder cancer	0.00032	0.00783	CcSEcCtD
Drospirenone—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000319	0.00779	CcSEcCtD
Drospirenone—Skin disorder—Gemcitabine—urinary bladder cancer	0.000316	0.00771	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000314	0.00767	CcSEcCtD
Drospirenone—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000313	0.00766	CcSEcCtD
Drospirenone—Affect lability—Epirubicin—urinary bladder cancer	0.000311	0.00761	CcSEcCtD
Drospirenone—Migraine—Epirubicin—urinary bladder cancer	0.000311	0.00761	CcSEcCtD
Drospirenone—Breast disorder—Methotrexate—urinary bladder cancer	0.000305	0.00747	CcSEcCtD
Drospirenone—Mood swings—Epirubicin—urinary bladder cancer	0.0003	0.00732	CcSEcCtD
Drospirenone—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000299	0.0073	CcSEcCtD
Drospirenone—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000297	0.00726	CcSEcCtD
Drospirenone—Skin disorder—Cisplatin—urinary bladder cancer	0.000294	0.00719	CcSEcCtD
Drospirenone—Affect lability—Doxorubicin—urinary bladder cancer	0.000288	0.00704	CcSEcCtD
Drospirenone—Migraine—Doxorubicin—urinary bladder cancer	0.000288	0.00704	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000287	0.00702	CcSEcCtD
Drospirenone—Breast disorder—Epirubicin—urinary bladder cancer	0.000286	0.00699	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00028	0.00685	CcSEcCtD
Drospirenone—Mood swings—Doxorubicin—urinary bladder cancer	0.000277	0.00678	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000276	0.00674	CcSEcCtD
Drospirenone—Skin disorder—Etoposide—urinary bladder cancer	0.000269	0.00659	CcSEcCtD
Drospirenone—Breast disorder—Doxorubicin—urinary bladder cancer	0.000265	0.00647	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000261	0.00639	CcSEcCtD
Drospirenone—Depression—Methotrexate—urinary bladder cancer	0.00026	0.00635	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000239	0.00585	CcSEcCtD
Drospirenone—Haemoglobin—Methotrexate—urinary bladder cancer	0.000235	0.00574	CcSEcCtD
Drospirenone—Haemorrhage—Methotrexate—urinary bladder cancer	0.000234	0.00572	CcSEcCtD
Drospirenone—Nausea—Thiotepa—urinary bladder cancer	0.000229	0.00561	CcSEcCtD
Drospirenone—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000221	0.0054	CcSEcCtD
Drospirenone—Haemoglobin—Epirubicin—urinary bladder cancer	0.00022	0.00538	CcSEcCtD
Drospirenone—Haemorrhage—Epirubicin—urinary bladder cancer	0.000219	0.00535	CcSEcCtD
Drospirenone—Angiopathy—Methotrexate—urinary bladder cancer	0.000212	0.00519	CcSEcCtD
Drospirenone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000207	0.00506	CcSEcCtD
Drospirenone—Mental disorder—Methotrexate—urinary bladder cancer	0.000205	0.00501	CcSEcCtD
Drospirenone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000204	0.00497	CcSEcCtD
Drospirenone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000203	0.00495	CcSEcCtD
Drospirenone—Angiopathy—Epirubicin—urinary bladder cancer	0.000199	0.00485	CcSEcCtD
Drospirenone—Nausea—Gemcitabine—urinary bladder cancer	0.000193	0.00472	CcSEcCtD
Drospirenone—Mental disorder—Epirubicin—urinary bladder cancer	0.000192	0.00469	CcSEcCtD
Drospirenone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000191	0.00468	CcSEcCtD
Drospirenone—Nausea—Fluorouracil—urinary bladder cancer	0.00019	0.00464	CcSEcCtD
Drospirenone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000184	0.00449	CcSEcCtD
Drospirenone—Nausea—Cisplatin—urinary bladder cancer	0.00018	0.0044	CcSEcCtD
Drospirenone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000177	0.00434	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000172	0.00421	CcSEcCtD
Drospirenone—AR—Androgen receptor signaling pathway—SRC—urinary bladder cancer	0.000167	0.00193	CbGpPWpGaD
Drospirenone—Nausea—Etoposide—urinary bladder cancer	0.000165	0.00403	CcSEcCtD
Drospirenone—AR—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	0.000164	0.00191	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	0.000164	0.0019	CbGpPWpGaD
Drospirenone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000163	0.00398	CcSEcCtD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—urinary bladder cancer	0.000163	0.00189	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000162	0.00189	CbGpPWpGaD
Drospirenone—Skin disorder—Methotrexate—urinary bladder cancer	0.000161	0.00394	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000161	0.00394	CcSEcCtD
Drospirenone—AR—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000161	0.00187	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000161	0.00186	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000157	0.00182	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000156	0.00182	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000156	0.00181	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—CDKN1A—urinary bladder cancer	0.000154	0.00179	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—PTEN—urinary bladder cancer	0.000154	0.00178	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—CDX2—urinary bladder cancer	0.000153	0.00178	CbGpPWpGaD
Drospirenone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000152	0.00373	CcSEcCtD
Drospirenone—NR3C2—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000152	0.00177	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—SMC1A—urinary bladder cancer	0.000152	0.00176	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000151	0.00176	CbGpPWpGaD
Drospirenone—Skin disorder—Epirubicin—urinary bladder cancer	0.000151	0.00369	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000149	0.00364	CcSEcCtD
Drospirenone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000149	0.00173	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000148	0.00171	CbGpPWpGaD
Drospirenone—NR3C2—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000146	0.0017	CbGpPWpGaD
Drospirenone—AR—Androgen receptor signaling pathway—EGFR—urinary bladder cancer	0.000146	0.00169	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000146	0.00169	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000145	0.00168	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000143	0.00351	CcSEcCtD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000142	0.00165	CbGpPWpGaD
Drospirenone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000141	0.00345	CcSEcCtD
Drospirenone—Skin disorder—Doxorubicin—urinary bladder cancer	0.00014	0.00342	CcSEcCtD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000137	0.00159	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000136	0.00157	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000135	0.00157	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000134	0.00156	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000134	0.00328	CcSEcCtD
Drospirenone—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000133	0.00154	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—ESR2—urinary bladder cancer	0.000132	0.00154	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	0.000132	0.00154	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000129	0.0015	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.000128	0.00148	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000127	0.00148	CbGpPWpGaD
Drospirenone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	0.000127	0.00147	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—EGFR—urinary bladder cancer	0.000125	0.00145	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000124	0.00304	CcSEcCtD
Drospirenone—AR—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	0.000122	0.00142	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTZ1—urinary bladder cancer	0.00012	0.00139	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—KRAS—urinary bladder cancer	0.000118	0.00137	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	0.000118	0.00137	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000117	0.00136	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000115	0.00134	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	0.000115	0.00133	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000114	0.00133	CbGpPWpGaD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000114	0.00133	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTO2—urinary bladder cancer	0.000114	0.00132	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NAT1—urinary bladder cancer	0.000114	0.00132	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	0.000112	0.0013	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	0.000112	0.0013	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000112	0.0013	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000112	0.0013	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000109	0.00127	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	0.000108	0.00126	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—HDAC4—urinary bladder cancer	0.000108	0.00126	CbGpPWpGaD
Drospirenone—BCHE—Phospholipid metabolism—PTEN—urinary bladder cancer	0.000106	0.00123	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	0.000104	0.00121	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—UGT2B7—urinary bladder cancer	0.000104	0.00121	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	0.000103	0.0012	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000102	0.00119	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—NCOR1—urinary bladder cancer	0.000102	0.00119	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000102	0.00118	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.000101	0.00117	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—HRAS—urinary bladder cancer	0.0001	0.00116	CbGpPWpGaD
Drospirenone—Nausea—Methotrexate—urinary bladder cancer	9.87e-05	0.00241	CcSEcCtD
Drospirenone—AR—Generic Transcription Pathway—NCOR1—urinary bladder cancer	9.85e-05	0.00114	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	9.78e-05	0.00114	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	9.77e-05	0.00113	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	9.75e-05	0.00113	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—IGFBP3—urinary bladder cancer	9.61e-05	0.00112	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—ERCC2—urinary bladder cancer	9.61e-05	0.00112	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	9.56e-05	0.00111	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CYP4B1—urinary bladder cancer	9.37e-05	0.00109	CbGpPWpGaD
Drospirenone—PTGS2—Disease—GSTO2—urinary bladder cancer	9.36e-05	0.00109	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	9.3e-05	0.00108	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—PPARG—urinary bladder cancer	9.27e-05	0.00108	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—SMC1A—urinary bladder cancer	9.25e-05	0.00107	CbGpPWpGaD
Drospirenone—Nausea—Epirubicin—urinary bladder cancer	9.24e-05	0.00226	CcSEcCtD
Drospirenone—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	9.16e-05	0.00106	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—GLI1—urinary bladder cancer	9.06e-05	0.00105	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	9.04e-05	0.00105	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	9.03e-05	0.00105	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	9.03e-05	0.00105	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	8.99e-05	0.00104	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	8.99e-05	0.00104	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	8.96e-05	0.00104	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	8.9e-05	0.00103	CbGpPWpGaD
Drospirenone—AR—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	8.87e-05	0.00103	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—SLC19A1—urinary bladder cancer	8.85e-05	0.00103	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	8.76e-05	0.00102	CbGpPWpGaD
Drospirenone—NR3C2—Generic Transcription Pathway—MYC—urinary bladder cancer	8.67e-05	0.00101	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PRSS3—urinary bladder cancer	8.63e-05	0.001	CbGpPWpGaD
Drospirenone—Nausea—Doxorubicin—urinary bladder cancer	8.55e-05	0.00209	CcSEcCtD
Drospirenone—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	8.54e-05	0.000991	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	8.3e-05	0.000964	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	8.29e-05	0.000962	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	8.27e-05	0.00096	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	8.1e-05	0.000941	CbGpPWpGaD
Drospirenone—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	8.07e-05	0.000937	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—ESR2—urinary bladder cancer	8.06e-05	0.000936	CbGpPWpGaD
Drospirenone—AR—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	8.03e-05	0.000932	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—ESR1—urinary bladder cancer	8.03e-05	0.000932	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.92e-05	0.00092	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.85e-05	0.000911	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTO2—urinary bladder cancer	7.84e-05	0.00091	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NAT1—urinary bladder cancer	7.84e-05	0.00091	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.75e-05	0.0009	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—ESR1—urinary bladder cancer	7.74e-05	0.000898	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.71e-05	0.000895	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	7.55e-05	0.000876	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	7.49e-05	0.000869	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—PPARG—urinary bladder cancer	7.32e-05	0.00085	CbGpPWpGaD
Drospirenone—PTGS2—Disease—SLC19A1—urinary bladder cancer	7.28e-05	0.000845	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	7.17e-05	0.000832	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PRSS3—urinary bladder cancer	7.09e-05	0.000823	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—PPARG—urinary bladder cancer	7.06e-05	0.00082	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	7.06e-05	0.00082	CbGpPWpGaD
Drospirenone—AR—Gene Expression—SMC1A—urinary bladder cancer	7.05e-05	0.000818	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—CREBBP—urinary bladder cancer	7.04e-05	0.000817	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.92e-05	0.000803	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—TYMP—urinary bladder cancer	6.9e-05	0.000801	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	6.85e-05	0.000795	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	6.78e-05	0.000787	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HDAC4—urinary bladder cancer	6.76e-05	0.000785	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	6.7e-05	0.000778	CbGpPWpGaD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.65e-05	0.000773	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.62e-05	0.000769	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.57e-05	0.000763	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	6.45e-05	0.000749	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	6.38e-05	0.000741	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NAT2—urinary bladder cancer	6.24e-05	0.000724	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—NCOR1—urinary bladder cancer	6.22e-05	0.000723	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—RBX1—urinary bladder cancer	6.21e-05	0.000721	CbGpPWpGaD
Drospirenone—AR—Gene Expression—ESR2—urinary bladder cancer	6.14e-05	0.000713	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	6.09e-05	0.000707	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PRSS3—urinary bladder cancer	5.94e-05	0.000689	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—ERCC2—urinary bladder cancer	5.85e-05	0.00068	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TSC1—urinary bladder cancer	5.84e-05	0.000678	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.81e-05	0.000674	CbGpPWpGaD
Drospirenone—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	5.62e-05	0.000653	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.62e-05	0.000652	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.61e-05	0.000651	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—JAG1—urinary bladder cancer	5.56e-05	0.000645	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—RRM2—urinary bladder cancer	5.38e-05	0.000625	CbGpPWpGaD
Drospirenone—PTGS2—Disease—LIG1—urinary bladder cancer	5.37e-05	0.000624	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	5.35e-05	0.000621	CbGpPWpGaD
Drospirenone—PGR—Generic Transcription Pathway—MYC—urinary bladder cancer	5.28e-05	0.000613	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	5.2e-05	0.000604	CbGpPWpGaD
Drospirenone—BCHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.12e-05	0.000595	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ENO2—urinary bladder cancer	4.99e-05	0.000579	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—HPGDS—urinary bladder cancer	4.99e-05	0.000579	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.96e-05	0.000576	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—ESR1—urinary bladder cancer	4.89e-05	0.000568	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTT1—urinary bladder cancer	4.84e-05	0.000562	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.76e-05	0.000553	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.76e-05	0.000553	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—TYMP—urinary bladder cancer	4.75e-05	0.000551	CbGpPWpGaD
Drospirenone—AR—Gene Expression—NCOR1—urinary bladder cancer	4.74e-05	0.000551	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.66e-05	0.000541	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.56e-05	0.000529	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.56e-05	0.000529	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—S100B—urinary bladder cancer	4.5e-05	0.000523	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—PPARG—urinary bladder cancer	4.46e-05	0.000518	CbGpPWpGaD
Drospirenone—AR—Gene Expression—ERCC2—urinary bladder cancer	4.46e-05	0.000518	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	4.34e-05	0.000504	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	4.3e-05	0.0005	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NAT2—urinary bladder cancer	4.29e-05	0.000498	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—CREBBP—urinary bladder cancer	4.29e-05	0.000498	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—MYC—urinary bladder cancer	4.18e-05	0.000485	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ENO2—urinary bladder cancer	4.1e-05	0.000476	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—IGF1—urinary bladder cancer	4.06e-05	0.000472	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—NCOR1—urinary bladder cancer	4.05e-05	0.00047	CbGpPWpGaD
Drospirenone—AR—Generic Transcription Pathway—MYC—urinary bladder cancer	4.02e-05	0.000467	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NQO1—urinary bladder cancer	4.02e-05	0.000467	CbGpPWpGaD
Drospirenone—BCHE—Neuronal System—HRAS—urinary bladder cancer	3.93e-05	0.000456	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.9e-05	0.000453	CbGpPWpGaD
Drospirenone—PTGS2—Disease—RBX1—urinary bladder cancer	3.89e-05	0.000451	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.83e-05	0.000444	CbGpPWpGaD
Drospirenone—AR—Gene Expression—ESR1—urinary bladder cancer	3.73e-05	0.000433	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—RRM2—urinary bladder cancer	3.71e-05	0.00043	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TERT—urinary bladder cancer	3.57e-05	0.000414	CbGpPWpGaD
Drospirenone—PTGS2—Disease—JAG1—urinary bladder cancer	3.48e-05	0.000404	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ENO2—urinary bladder cancer	3.43e-05	0.000398	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—HPGDS—urinary bladder cancer	3.43e-05	0.000398	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.41e-05	0.000396	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.4e-05	0.000395	CbGpPWpGaD
Drospirenone—AR—Gene Expression—PPARG—urinary bladder cancer	3.4e-05	0.000395	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTP1—urinary bladder cancer	3.35e-05	0.000389	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTT1—urinary bladder cancer	3.33e-05	0.000387	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.28e-05	0.000381	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FGFR3—urinary bladder cancer	3.27e-05	0.00038	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—CXCL8—urinary bladder cancer	3.27e-05	0.000379	CbGpPWpGaD
Drospirenone—AR—Gene Expression—CREBBP—urinary bladder cancer	3.27e-05	0.000379	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.24e-05	0.000377	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ESR1—urinary bladder cancer	3.18e-05	0.000369	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—TYMS—urinary bladder cancer	3.12e-05	0.000362	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GSTM1—urinary bladder cancer	3.08e-05	0.000358	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—NCOR1—urinary bladder cancer	3.08e-05	0.000358	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—GPX1—urinary bladder cancer	2.95e-05	0.000343	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—ERCC2—urinary bladder cancer	2.9e-05	0.000336	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CREBBP—urinary bladder cancer	2.79e-05	0.000324	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NQO1—urinary bladder cancer	2.77e-05	0.000321	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IGF1—urinary bladder cancer	2.75e-05	0.000319	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—MTHFR—urinary bladder cancer	2.72e-05	0.000316	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—MYC—urinary bladder cancer	2.54e-05	0.000295	CbGpPWpGaD
Drospirenone—PTGS2—Disease—NCOR1—urinary bladder cancer	2.53e-05	0.000294	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—RHOA—urinary bladder cancer	2.52e-05	0.000293	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ERCC2—urinary bladder cancer	2.38e-05	0.000276	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.34e-05	0.000272	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—ERBB2—urinary bladder cancer	2.33e-05	0.000271	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTP1—urinary bladder cancer	2.31e-05	0.000268	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MTHFR—urinary bladder cancer	2.24e-05	0.00026	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.23e-05	0.000259	CbGpPWpGaD
Drospirenone—PTGS2—Disease—TERT—urinary bladder cancer	2.23e-05	0.000259	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	2.21e-05	0.000257	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PPARG—urinary bladder cancer	2.21e-05	0.000256	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—TYMS—urinary bladder cancer	2.15e-05	0.000249	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—CREBBP—urinary bladder cancer	2.12e-05	0.000246	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—NCOR1—urinary bladder cancer	2.12e-05	0.000246	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GSTM1—urinary bladder cancer	2.12e-05	0.000246	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—IL2—urinary bladder cancer	2.11e-05	0.000246	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CCND1—urinary bladder cancer	2.06e-05	0.000239	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FGFR3—urinary bladder cancer	2.05e-05	0.000238	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—GPX1—urinary bladder cancer	2.03e-05	0.000236	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MMP9—urinary bladder cancer	2e-05	0.000232	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.99e-05	0.000232	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.99e-05	0.000231	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—PTEN—urinary bladder cancer	1.99e-05	0.000231	CbGpPWpGaD
Drospirenone—AR—Gene Expression—MYC—urinary bladder cancer	1.94e-05	0.000225	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—EP300—urinary bladder cancer	1.9e-05	0.00022	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.87e-05	0.000218	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—SRC—urinary bladder cancer	1.85e-05	0.000214	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CREBBP—urinary bladder cancer	1.74e-05	0.000202	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PTGS2—urinary bladder cancer	1.74e-05	0.000202	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—MYC—urinary bladder cancer	1.65e-05	0.000192	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—EGFR—urinary bladder cancer	1.62e-05	0.000188	CbGpPWpGaD
Drospirenone—PTGS2—Disease—RHOA—urinary bladder cancer	1.58e-05	0.000183	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KRAS—urinary bladder cancer	1.53e-05	0.000177	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.52e-05	0.000176	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—PTEN—urinary bladder cancer	1.51e-05	0.000176	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.46e-05	0.000169	CbGpPWpGaD
Drospirenone—PTGS2—Disease—ERBB2—urinary bladder cancer	1.46e-05	0.000169	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—EP300—urinary bladder cancer	1.44e-05	0.000168	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—TP53—urinary bladder cancer	1.36e-05	0.000158	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—HRAS—urinary bladder cancer	1.3e-05	0.000151	CbGpPWpGaD
Drospirenone—PTGS2—Disease—CDKN1A—urinary bladder cancer	1.25e-05	0.000145	CbGpPWpGaD
Drospirenone—PTGS2—Disease—PTEN—urinary bladder cancer	1.24e-05	0.000145	CbGpPWpGaD
Drospirenone—PTGS2—Disease—EP300—urinary bladder cancer	1.19e-05	0.000138	CbGpPWpGaD
Drospirenone—PTGS2—Disease—SRC—urinary bladder cancer	1.15e-05	0.000134	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—PTEN—urinary bladder cancer	1.04e-05	0.000121	CbGpPWpGaD
Drospirenone—PTGS2—Disease—MYC—urinary bladder cancer	1.03e-05	0.00012	CbGpPWpGaD
Drospirenone—PTGS2—Disease—EGFR—urinary bladder cancer	1.01e-05	0.000117	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—EP300—urinary bladder cancer	9.94e-06	0.000115	CbGpPWpGaD
Drospirenone—PTGS2—Disease—KRAS—urinary bladder cancer	9.56e-06	0.000111	CbGpPWpGaD
Drospirenone—PTGS2—Disease—HRAS—urinary bladder cancer	8.12e-06	9.43e-05	CbGpPWpGaD
